5,7-Dihydroxytryptamine hydrobromide
| Code | Size | Price |
|---|
| CDX-H0026-M010 | 10 mg | £194.00 |
Quantity:
| CDX-H0026-M025 | 25 mg | £377.00 |
Quantity:
| CDX-H0026-M250 | 250 mg | £2,940.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
5,7-DHT; 3-(2-Aminoethyl)-1H-indole-5,7-diol
Appearance:
Grey-brown powder.
CAS:
31363-74-3 (free base)
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.Protect from light and moisture.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C10H12N2O2.BrH/c11-2-1-6-5-12-10-8(6)3-7(13)4-9(10)14;/h3-5,12-14H,1-2,11H2;1H
InChiKey:
KVRZGCBQKAJSBN-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 31363-74-3 (free base). Formula: C10H12N2O2 . HBr. MW: 192.2 . 80.9. Synthetic Autofluorescent serotonin derivative. Serotonergic neurotoxin, depleting serotonin and norepinephrine. Can be used for the identification of living serotonergic neurons even in the presence of dopaminergic neurons. Its selectively uptaken into 5-hydroxytryptamine neurons. It?s oxidation products are often more potent then the parent product.
MDL:
MFCD05260760
Molecular Formula:
C10H12N2O2 . HBr
Molecular Weight:
192.2 . 80.9
Package Type:
Vial
Precautions:
P261, P305, P351, P338
Product Description:
Autofluorescent serotonin derivative. Serotonergic neurotoxin, depleting serotonin and norepinephrine. Can be used for the identification of living serotonergic neurons even in the presence of dopaminergic neurons. Its selectively uptaken into 5-hydroxytryptamine neurons. It?s oxidation products are often more potent then the parent product.
Purity:
>95% (HPLC)
Signal word:
Warning
SMILES:
[Br-].[NH3+]CCC1=CNC2=C(O)C=C(O)C=C12
Solubility Chemicals:
Soluble in water.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Fluorescent Reagents
UNSPSC Number:
41105331
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) H.G. Baumgarten, et al.; Acta Physiol. Scand. Suppl. 391, 1 (1973) | (2) B. Allis & G. Cohen; Eur. J. Pharmacol. 43, 269 (1977) | (3) K. Fuxe, et al.; Ann. N. Y. Acad. Sci. 305, 346 (1978) | (4) M.Z. Wrona, et al.; J. Med. Chem. 29, 499 (1986) | (5) A.K. Sinhababu & R.T. Borchardt; Neurochem. Int. 12, 273 (1988) | (6) K.T. Finnegan, et al.; Brain. Res. 496, 251 (1989) | (7) H. Franke,et al.; Naunyn Schmiedebergs Arch. Pharmacol. 366, 315 (2002)